Literature DB >> 266969

HLA linked resistance factors and survival in acute myelogenous leukemia.

R T Oliver, A Pillai, P T Klouda, S D Lawler.   

Abstract

The concept that HLA-linked immune response genes may influence survival of patients with malignant disease has been investigated by performing HLA typing on a series of 150 patients with acute myelogenous leukemia. Patients with A1 and B8 and/or A2 and B12 survival longer than patients without either of these pairs of antigens in association. However, after correction of the statistical probability for the number of A and B locus combinations theoretically possible, these differences are not statistically significant. Clarification of this must await independent analysis of other series and more direct approaches to the study of immune response genes in man.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 266969     DOI: 10.1002/1097-0142(197706)39:6<2337::aid-cncr2820390603>3.0.co;2-x

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Long survival in acute myelogenous leukaemia.

Authors:  C B Freeman; R Harris; G M Taylor
Journal:  Br Med J (Clin Res Ed)       Date:  1981-07-11

2.  Increased frequency of B8/DR3 in scleroderma and association of the haplotype with impaired cellular immune response.

Authors:  C G Kallenberg; J M Van der Voort-Beelen; J D'Amaro; T H The
Journal:  Clin Exp Immunol       Date:  1981-03       Impact factor: 4.330

3.  Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma.

Authors:  C Bain; Y Merrouche; I Puisieux; J Y Blay; S Negrier; V Bonadona; C Lasset; F Lanier; A Duc; L Gebuhrer; T Philip; M C Favrot
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  Definition of a possible genetic basis for susceptibility to acute myelogenous leukemia associated with the presence of a polymorphic Ia epitope.

Authors:  S Seremetis; J Cuttner; R Winchester
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

5.  Chronic myelocytic leukaemia: HLA association and decreased erythrocyte C3b receptor expression.

Authors:  P Ruuska; S Silvennoinen-Kassinen; T Timonen; A Tiilikainen
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

6.  The HLA system and immunological defence against cancer: a review.

Authors:  R T Oliver
Journal:  J R Soc Med       Date:  1978-01       Impact factor: 18.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.